{
    "root": "303ec748-0ce2-d2bb-e063-6394a90a5813",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "QUETIAPINE FUMARATE",
    "value": "20250313",
    "ingredients": [
        {
            "name": "HYPROMELLOSE 2208 (4000 MPA.S)",
            "code": "39J80LT57T"
        },
        {
            "name": "HYPROMELLOSE 2208 (100 MPA.S)",
            "code": "B1QE5P712K"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "POLYETHYLENE GLYCOL 4000",
            "code": "4R4HFI6D95"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "QUETIAPINE FUMARATE",
            "code": "2S3PL1B6UJ"
        }
    ],
    "indications": "quetiapine extended-release tablet atypical antipsychotic indicated treatment : schizophrenia ( 1.1 ) bipolar disorder , manic , mixed episodes ( 1.2 ) bipolar disorder , depressive episodes ( 1.2 ) major depressive disorder , adjunctive therapy antidepressants ( 1.3 )",
    "contraindications": "swallow tablets whole split , chew crush ( 2.1 ) take without food light meal ( approx . 300 calories ) ( 2.1 ) administer daily , preferably evening ( 2.1 ) geriatric : consider lower starting dose ( 50 mg/day ) , slower titration , careful monitoring initial dosing period elderly . ( 2.3 , 8.5 ) hepatic impairment : lower starting dose ( 50 mg/day ) slower titration may needed ( 2.4 , 8.7 , 12.3 ) indication initial dose recommended dose maximum dose schizophrenia- adults ( 2.2 ) 300 mg/day 400 800 mg/day 800 mg/day schizophrenia-adolescents ( 13 17 years ) ( 2.2 ) 50 mg/day 400 800 mg/day 800 mg/day bipolar disorder manic mixed-acute monotherapy adjunct lithium divalproex-adults ( 2.2 ) 300 mg/day 400 800 mg/day 800 mg/day bipolar disorder , manic acute monotherapy -children adolescents ( 10 17 years ) ( 2.2 ) 50 mg/day 400 600 mg/day 600 mg/day bipolar disorder , depressive episodes-adults ( 2.2 ) 50 mg/day 300 mg/day 300 mg/day major depressive disorder , adjunctive therapy antidepressants-adults ( 2.2 ) 50 mg/day 150 300 mg/day 300 mg/day",
    "warningsAndPrecautions": "quetiapine extended-release tablets , usp 50 mg peach colored , capsule shaped , biconvex , film coated tablets , debossed ‘ ab 1 ’ one side plain supplied bottles 60 tablets child-resistant closure ( ndc 68001-511-06 ) . store quetiapine extended-release tablets , usp 50 mg 20ºc 25ºc ( 68 ºf 77 ºf ) . [ usp controlled room temperature ] .",
    "adverseReactions": "hypersensitivity quetiapine excipients quetiapine extended-release tablets formulation . anaphylactic reported patients treated quetiapine extended-release tablets .",
    "indications_original": "Quetiapine Extended-release tablet is an atypical antipsychotic indicated for the treatment of: Schizophrenia (1.1) Bipolar I disorder, manic, or mixed episodes (1.2) Bipolar disorder, depressive episodes (1.2) Major depressive disorder, adjunctive therapy with antidepressants (1.3)",
    "contraindications_original": "Swallow tablets whole and do not split, chew or crush (2.1) Take without food or with a light meal (approx. 300 calories) (2.1) Administer once daily, preferably in the evening (2.1) Geriatric Use: Consider a lower starting dose (50 mg/day), slower titration, and careful monitoring during the initial dosing period in the elderly. ( 2.3 , 8.5 ) Hepatic Impairment: Lower starting dose (50 mg/day) and slower titration may be needed ( 2.4 , 8.7 , 12.3 ) Indication Initial Dose Recommended Dose Maximum Dose Schizophrenia- Adults (2.2) 300 mg/day 400 to 800 mg/day 800 mg/day Schizophrenia-Adolescents (13 to 17 years )(2.2) 50 mg/day 400 to 800 mg/day 800 mg/day Bipolar I Disorder manic or mixed-Acute monotherapy or adjunct to lithium or divalproex-Adults (2.2) 300 mg/day 400 to 800 mg/day 800 mg/day Bipolar I Disorder, manic Acute monotherapy -Children and Adolescents (10 to 17 years) (2.2) 50 mg/day 400 to 600 mg/day 600 mg/day Bipolar Disorder, Depressive Episodes-Adults (2.2) 50 mg/day 300 mg/day 300 mg/day Major Depressive Disorder, Adjunctive Therapy with Antidepressants-Adults (2.2) 50 mg/day 150 to 300 mg/day 300 mg/day",
    "warningsAndPrecautions_original": "Quetiapine Extended-release tablets, USP 50 mg peach colored, capsule shaped, biconvex, film coated tablets, debossed with ‘AB 1’ on one side and plain on other are supplied in bottles of 60 tablets with child-resistant closure (NDC 68001-511-06).                \n       \n                  \n                  Store quetiapine extended-release tablets, USP 50 mg at 20ºC to 25ºC (68 ºF to 77 ºF). [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Hypersensitivity to quetiapine or to any excipients in the quetiapine extended-release tablets formulation.  Anaphylactic reactions have been reported in patients treated with quetiapine extended-release tablets."
}